Omar Nadeem

Also affiliated with Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 17 papers. Top paper: “Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma”.

Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma

New England Journal of Medicine(2022)10.1056/nejmoa2204925

N/A

6.2DataRank · unranked

474 citations

Susanna Jacobus, Edie Weller, Hani Hassoun, Sagar Lonial, Noopur Raje +51 more

Long-Term Follow-Up Defines the Population That Benefits from Early Interception in a High-Risk Smoldering Multiple Myeloma Clinical Trial Using the Combination of Ixazomib, Lenalidomide, and Dexamethasone

medRxiv(2024)10.1101/2024.04.19.24306082

N/A

0.343DataRank · unranked

6 citations

Michelle P. Aranha, Robert Redd, Michael Timonian, Sophie Magidson, Elizabeth D. Lightbody +17 more

Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma

Cancer Cell(2022)10.1016/j.ccell.2022.10.017

N/A

0DataRank · unranked

64 citations

Michelle P. Aranha, Robert Redd, Joanna Bagińska, Nicholas J. Haradhvala, Margaret Hallisey +34 more

MinimuMM-seq: Genome Sequencing of Circulating Tumor Cells for Minimally Invasive Molecular Characterization of Multiple Myeloma Pathology

Cancer Discovery(2022)10.1158/2159-8290.cd-22-0482

N/A

0DataRank · unranked

38 citations

Jean-Baptiste Alberge, Elizabeth D. Lightbody, Cody J. Boehner, Andrew Dunford, Romanos Sklavenitis‐Pistofidis +19 more

Characterizing dry mass and volume changes in human multiple myeloma cells upon treatment with proteotoxic and genotoxic drugs

bioRxiv (Cold Spring Harbor Laboratory)(2022)10.1101/2022.03.18.484926

N/A

0DataRank · unranked

3 citations

Maria Moscvin, Seungeun Oh, Tianzeng Chen, Wonshik Choi, Benjamin Evans +9 more

Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study

The Lancet Haematology(2023)10.1016/s2352-3026(22)00386-6

N/A

0DataRank · unranked

81 citations

Federico Ferrari, Samuel S. Freeman, Robert Redd, Habib El‐Khoury, Jacqueline Perry +29 more

Respiratory infections predominate after day 100 following B-cell maturation antigen–directed CAR T-cell therapy

Blood Advances(2023)10.1182/bloodadvances.2023010524

N/A

0DataRank · unranked

39 citations

Megha Tandon, Joseph Hong, Omar Nadeem, Adam S. Sperling, Noopur Raje +5 more

Bispecific Monoclonal Antibodies in Multiple Myeloma: Data from ASH 2022: A Podcast

Advances in Therapy(2023)10.1007/s12325-023-02551-9

N/A

0DataRank · unranked

10 citations

Omar Nadeem, Ola Landgren

Clinical Outcomes of Monoclonal Gammopathy of Renal Significance Without Detectable Clones

Kidney International Reports(2023)10.1016/j.ekir.2023.09.022

N/A

0DataRank · unranked

9 citations

Umut Selamet, Shonali Midha, Omar Nadeem, Jacob P. Laubach, Helmut G. Rennke +2 more

Characterizing dry mass and volume changes in human multiple myeloma cells upon treatment with proteotoxic and genotoxic drugs

Clinical and Experimental Medicine(2023)10.1007/s10238-023-01124-y

N/A

0DataRank · unranked

7 citations

Maria Moscvin, Seungeun Oh, Tianzeng Chen, Wonshik Choi, Benjamin Evans +9 more

Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma

Blood(2024)10.1182/blood.2024025945

N/A

0DataRank · unranked

130 citations

Krina K. Patel, Lauren C. Peres, Radhika Bansal, Mehmet H. Kocoglu, Leyla Shune +33 more

Patient preferences for intervention in the setting of precursor multiple myeloma

Blood Cancer Journal(2024)10.1038/s41408-024-01161-0

N/A

0DataRank · unranked

1 citations

K Downey, Jacqueline Perry, Brittany Fisher-Longden, Timothy R. Rebbeck, Urvi A. Shah +5 more

Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trial

Nature Communications(2025)10.1038/s41467-024-55308-5

N/A

0DataRank · unranked

14 citations

Michelle P. Aranha, Robert Redd, Michael Timonian, Sophie Magidson, Elizabeth D. Lightbody +17 more

Distress and symptom burden in patients with monoclonal gammopathy of undetermined significance and smoldering myeloma

Blood Advances(2025)10.1182/bloodadvances.2024015575

N/A

0DataRank · unranked

3 citations

Jennifer E. Carroll, Jaqueline Perry, Katherine Padgett, Benjamin Harris, Vidhi Patel +5 more

A clinical perspective on plasma cell leukemia; current status and future directions

Blood Cancer Journal(2021)10.1038/s41408-021-00414-6

N/A

0DataRank · unranked

60 citations

Leona Holmberg, Omar Nadeem, Paul G. Richardson, Sherilyn A. Tuazon

Enhanced Risk Stratification of Smoldering Multiple Myeloma with Dynamic Biomarkers: A Multinational, Multicenter Study including 2,270 Participants (PANGEA 2.0)

Research Square(2025)10.21203/rs.3.rs-6696313/v1

N/A

0DataRank · unranked

0 citations

Daniel L. Schwartz, Susanna Gentile, K. Elias, Tulika Gupta, Jacqueline Perry +43 more

Finding the Optimal Partner to Pair with Bispecific Antibody Therapy for Multiple Myeloma

Blood Cancer Discovery(2021)10.1158/2643-3230.bcd-21-0073

N/A

0DataRank · unranked

6 citations

Omar Nadeem, Eric L. Smith, Cédric Louvet